Comparative Pharmacology
Head-to-head clinical analysis: MEZOFY versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEZOFY versus VONTROL.
MEZOFY vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEZOFY is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
MEZOFY (mexiletine) 200 mg orally every 8 hours; may increase to 300 mg every 8 hours if needed.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
Terminal half-life: 8-12 hours (mean 10 h); prolonged in renal impairment (up to 24 h in CrCl <30 mL/min)
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Renal: 60% unchanged; biliary/fecal: 25% as metabolites; 15% other
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic/Antivertigo
Antiemetic